Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jun;80(8):1223–1230. doi: 10.1038/sj.bjc.6690489

Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase

X Wang 1,2, G P Doherty 1,2, M K Leith 1,3, T J Curphey 4, A Begleiter 1,2,3
PMCID: PMC2362377  PMID: 10376975

Abstract

DT-diaphorase is a two-electron reducing enzyme that activates the bioreductive anti-tumour agent, mitomycin C (MMC). Cell lines having elevated levels of DT-diaphorase are generally more sensitive to MMC. We have shown that DT-diaphorase can be induced in human tumour cells by a number of compounds, including 1,2-dithiole-3-thione. In this study, we investigated whether induction of DT-diaphorase could enhance the cytotoxic activity of MMC in six human tumour cell lines representing four tumour types. DT-diaphorase was induced by many dietary inducers, including propyl gallate, dimethyl maleate, dimethyl fumarate and sulforaphane. The cytotoxicity of MMC was significantly increased in four tumour lines with the increase ranging from 1.4- to threefold. In contrast, MMC activity was not increased in SK-MEL-28 human melanoma cells and AGS human gastric cancer cells, cell lines that have high base levels of DT-diaphorase activity. Toxicity to normal human marrow cells was increased by 50% when MMC was combined with 1,2-dithiole-3-thione, but this increase was small in comparison with the threefold increase in cytotoxicity to tumour cells. This study demonstrates that induction of DT-diaphorase can increase the cytotoxic activity of MMC in human tumour cell lines, and suggests that it may be possible to use non-toxic inducers of DT-diaphorase to enhance the efficacy of bioreductive anti-tumour agents. © 1999 Cancer Research Campaign

Keywords: mitomycin C, DT-diaphorase, cytotoxicity, enzyme inducers

Full Text

The Full Text of this article is available as a PDF (150.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams G. E., Stratford I. J. Bioreductive drugs for cancer therapy: the search for tumor specificity. Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):231–238. doi: 10.1016/0360-3016(94)90267-4. [DOI] [PubMed] [Google Scholar]
  2. Appelt L. C., Reicks M. M. Soy feeding induces phase II enzymes in rat tissues. Nutr Cancer. 1997;28(3):270–275. doi: 10.1080/01635589709514587. [DOI] [PubMed] [Google Scholar]
  3. Barham H. M., Inglis R., Chinje E. C., Stratford I. J. Development and validation of a spectrophotometric assay for measuring the activity of NADH: cytochrome b5 reductase in human tumour cells. Br J Cancer. 1996 Oct;74(8):1188–1193. doi: 10.1038/bjc.1996.515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Beall H. D., Liu Y., Siegel D., Bolton E. M., Gibson N. W., Ross D. Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin. Biochem Pharmacol. 1996 Mar 8;51(5):645–652. doi: 10.1016/s0006-2952(95)00223-5. [DOI] [PubMed] [Google Scholar]
  5. Beall H. D., Murphy A. M., Siegel D., Hargreaves R. H., Butler J., Ross D. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol. 1995 Sep;48(3):499–504. [PubMed] [Google Scholar]
  6. Bedikian A. Y., Legha S. S., Eton O., Buzaid A. C., Papadopoulos N., Coates S., Simmons T., Neefe J., von Roemeling R. Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. Ann Oncol. 1997 Apr;8(4):363–367. doi: 10.1023/a:1008249232000. [DOI] [PubMed] [Google Scholar]
  7. Begleiter A., Leith M. K., Curphey T. J. Induction of DT-diaphorase by 1,2-dithiole-3-thione and increase of antitumour activity of bioreductive agents. Br J Cancer Suppl. 1996 Jul;27:S9–14. [PMC free article] [PubMed] [Google Scholar]
  8. Begleiter A., Robotham E., Lacey G., Leith M. K. Increased sensitivity of quinone resistant cells to mitomycin C. Cancer Lett. 1989 Jun;45(3):173–176. doi: 10.1016/0304-3835(89)90073-6. [DOI] [PubMed] [Google Scholar]
  9. Begleiter A., Robotham E., Leith M. K. Role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under hypoxia. Mol Pharmacol. 1992 Apr;41(4):677–682. [PubMed] [Google Scholar]
  10. Begleiter A., Verburg L., Ashique A., Lee K., Israels L. G., Mowat M. R., Johnston J. B. Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-beta-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia. 1995 Nov;9(11):1875–1881. [PubMed] [Google Scholar]
  11. Belcourt M. F., Hodnick W. F., Rockwell S., Sartorelli A. C. Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):456–460. doi: 10.1073/pnas.93.1.456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Belinsky M., Jaiswal A. K. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev. 1993 Jun;12(2):103–117. doi: 10.1007/BF00689804. [DOI] [PubMed] [Google Scholar]
  13. Beyer R. E., Segura-Aguilar J. E., Ernster L. The anticancer enzyme DT diaphorase is induced selectively in liver during ascites hepatoma growth. Anticancer Res. 1988 Mar-Apr;8(2):233–238. [PubMed] [Google Scholar]
  14. Boyer M. J. Bioreductive agents: a clinical update. Oncol Res. 1997;9(6-7):391–395. [PubMed] [Google Scholar]
  15. Coia L. R. The use of mitomycin in esophageal cancer. Oncology. 1993 Apr;50 (Suppl 1):53–60. doi: 10.1159/000227247. [DOI] [PubMed] [Google Scholar]
  16. Cummings B. J., Keane T. J., O'Sullivan B., Wong C. S., Catton C. N. Mitomycin in anal canal carcinoma. Oncology. 1993 Apr;50 (Suppl 1):63–69. doi: 10.1159/000227248. [DOI] [PubMed] [Google Scholar]
  17. Doherty G. P., Leith M. K., Wang X., Curphey T. J., Begleiter A. Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on anti-tumour activity of bioreductive agents. Br J Cancer. 1998 Apr;77(8):1241–1252. doi: 10.1038/bjc.1998.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Egner P. A., Kensler T. W., Prestera T., Talalay P., Libby A. H., Joyner H. H., Curphey T. J. Regulation of phase 2 enzyme induction by oltipraz and other dithiolethiones. Carcinogenesis. 1994 Feb;15(2):177–181. doi: 10.1093/carcin/15.2.177. [DOI] [PubMed] [Google Scholar]
  19. Fitzsimmons S. A., Workman P., Grever M., Paull K., Camalier R., Lewis A. D. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst. 1996 Mar 6;88(5):259–269. doi: 10.1093/jnci/88.5.259. [DOI] [PubMed] [Google Scholar]
  20. Fujita K., Kubota T., Matsuzaki S. W., Otani Y., Watanabe M., Teramoto T., Kumai K., Kitajima M. Further evidence for the value of the chemosensitivity test in deciding appropriate chemotherapy for advanced gastric cancer. Anticancer Res. 1998 May-Jun;18(3B):1973–1978. [PubMed] [Google Scholar]
  21. Gustafson D. L., Pritsos C. A. Bioactivation of mitomycin C by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors. J Natl Cancer Inst. 1992 Aug 5;84(15):1180–1185. doi: 10.1093/jnci/84.15.1180. [DOI] [PubMed] [Google Scholar]
  22. Habig W. H., Pabst M. J., Jakoby W. B. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 1974 Nov 25;249(22):7130–7139. [PubMed] [Google Scholar]
  23. Hodnick W. F., Sartorelli A. C. Reductive activation of mitomycin C by NADH:cytochrome b5 reductase. Cancer Res. 1993 Oct 15;53(20):4907–4912. [PubMed] [Google Scholar]
  24. Hortobagyi G. N. Mitomycin: its evolving role in the treatment of breast cancer. Oncology. 1993 Apr;50 (Suppl 1):1–8. [PubMed] [Google Scholar]
  25. Jaiswal A. K., Burnett P., Adesnik M., McBride O. W. Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6. Biochemistry. 1990 Feb 20;29(7):1899–1906. doi: 10.1021/bi00459a034. [DOI] [PubMed] [Google Scholar]
  26. Jaiswal A. K. Human NAD(P)H:quinone oxidoreductase (NQO1) gene structure and induction by dioxin. Biochemistry. 1991 Nov 5;30(44):10647–10653. doi: 10.1021/bi00108a007. [DOI] [PubMed] [Google Scholar]
  27. Johnston J. B., Verburg L., Shore T., Williams M., Israels L. G., Begleiter A. Combination therapy with nucleoside analogs and alkylating agents. Leukemia. 1994 Apr;8 (Suppl 1):S140–S143. [PubMed] [Google Scholar]
  28. Kensler T. W., Helzlsouer K. J. Oltipraz: clinical opportunities for cancer chemoprevention. p. J Cell Biochem Suppl. 1995;22:101–107. doi: 10.1002/jcb.240590813. [DOI] [PubMed] [Google Scholar]
  29. Kirkpatrick D. L., Duke M., Goh T. S. Chemosensitivity testing of fresh human leukemia cells using both a dye exclusion assay and a tetrazolium dye (MTT) assay. Leuk Res. 1990;14(5):459–466. doi: 10.1016/0145-2126(90)90033-6. [DOI] [PubMed] [Google Scholar]
  30. Lown J. W., Begleiter A., Johnson D., Morgan A. R. Studies related to antitumor antibiotics. Part V. Reactions of mitomycin C with DNA examined by ethidium fluorescence assay. Can J Biochem. 1976 Feb;54(2):110–119. doi: 10.1139/o76-018. [DOI] [PubMed] [Google Scholar]
  31. Malkinson A. M., Siegel D., Forrest G. L., Gazdar A. F., Oie H. K., Chan D. C., Bunn P. A., Mabry M., Dykes D. J., Harrison S. D. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cł. Cancer Res. 1992 Sep 1;52(17):4752–4757. [PubMed] [Google Scholar]
  32. Manson M. M., Ball H. W., Barrett M. C., Clark H. L., Judah D. J., Williamson G., Neal G. E. Mechanism of action of dietary chemoprotective agents in rat liver: induction of phase I and II drug metabolizing enzymes and aflatoxin B1 metabolism. Carcinogenesis. 1997 Sep;18(9):1729–1738. doi: 10.1093/carcin/18.9.1729. [DOI] [PubMed] [Google Scholar]
  33. Marshall R. S., Rauth A. M. Modification of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in Chinese hamster ovary cells and a repair-deficient mutant. Cancer Res. 1986 Jun;46(6):2709–2713. [PubMed] [Google Scholar]
  34. Marín A., López de Cerain A., Hamilton E., Lewis A. D., Martinez-Peñuela J. M., Idoate M. A., Bello J. DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. Br J Cancer. 1997;76(7):923–929. doi: 10.1038/bjc.1997.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Mikami K., Naito M., Tomida A., Yamada M., Sirakusa T., Tsuruo T. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Res. 1996 Jun 15;56(12):2823–2826. [PubMed] [Google Scholar]
  36. Miller V. A., Ng K. K., Grant S. C., Kindler H., Pizzo B., Heelan R. T., von Roemeling R., Kris M. G. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 1997 Dec;8(12):1269–1271. doi: 10.1023/a:1008219125746. [DOI] [PubMed] [Google Scholar]
  37. Nishiyama M., Saeki S., Aogi K., Hirabayashi N., Toge T. Relevance of DT-diaphorase activity to mitomycin C (MMC) efficacy on human cancer cells: differences in in vitro and in vivo systems. Int J Cancer. 1993 Apr 1;53(6):1013–1016. doi: 10.1002/ijc.2910530626. [DOI] [PubMed] [Google Scholar]
  38. Nishiyama M., Suzuki K., Kumazaki T., Yamamoto W., Toge T., Okamura T., Kurisu K. Molecular targeting of mitomycin C chemotherapy. Int J Cancer. 1997 Aug 7;72(4):649–656. doi: 10.1002/(sici)1097-0215(19970807)72:4<649::aid-ijc17>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  39. Plumb J. A., Gerritsen M., Milroy R., Thomson P., Workman P. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):295–299. doi: 10.1016/0360-3016(94)90278-x. [DOI] [PubMed] [Google Scholar]
  40. Prestera T., Holtzclaw W. D., Zhang Y., Talalay P. Chemical and molecular regulation of enzymes that detoxify carcinogens. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2965–2969. doi: 10.1073/pnas.90.7.2965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Pritsos C. A., Sartorelli A. C. Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics. Cancer Res. 1986 Jul;46(7):3528–3532. [PubMed] [Google Scholar]
  42. Prochaska H. J., Santamaria A. B. Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers. Anal Biochem. 1988 Mar;169(2):328–336. doi: 10.1016/0003-2697(88)90292-8. [DOI] [PubMed] [Google Scholar]
  43. Riley R. J., Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharmacol. 1992 Apr 15;43(8):1657–1669. doi: 10.1016/0006-2952(92)90694-e. [DOI] [PubMed] [Google Scholar]
  44. Rockwell S., Sartorelli A. C., Tomasz M., Kennedy K. A. Cellular pharmacology of quinone bioreductive alkylating agents. Cancer Metastasis Rev. 1993 Jun;12(2):165–176. doi: 10.1007/BF00689808. [DOI] [PubMed] [Google Scholar]
  45. Ross D., Beall H., Traver R. D., Siegel D., Phillips R. M., Gibson N. W. Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies. Oncol Res. 1994;6(10-11):493–500. [PubMed] [Google Scholar]
  46. Ross D., Siegel D., Beall H., Prakash A. S., Mulcahy R. T., Gibson N. W. DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C. Cancer Metastasis Rev. 1993 Jun;12(2):83–101. doi: 10.1007/BF00689803. [DOI] [PubMed] [Google Scholar]
  47. Schellens J. H., Planting A. S., van Acker B. A., Loos W. J., de Boer-Dennert M., van der Burg M. E., Koier I., Krediet R. T., Stoter G., Verweij J. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. J Natl Cancer Inst. 1994 Jun 15;86(12):906–912. doi: 10.1093/jnci/86.12.906. [DOI] [PubMed] [Google Scholar]
  48. Schlager J. J., Powis G. Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer. 1990 Mar 15;45(3):403–409. doi: 10.1002/ijc.2910450304. [DOI] [PubMed] [Google Scholar]
  49. Smitskamp-Wilms E., Giaccone G., Pinedo H. M., van der Laan B. F., Peters G. J. DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Br J Cancer. 1995 Oct;72(4):917–921. doi: 10.1038/bjc.1995.433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Spain R. C. The case for mitomycin in non-small cell lung cancer. Oncology. 1993 Apr;50 (Suppl 1):35–50. doi: 10.1159/000227246. [DOI] [PubMed] [Google Scholar]
  51. Strobel H. W., Dignam J. D. Purification and properties of NADPH-cytochrome P-450 reductase. Methods Enzymol. 1978;52:89–96. doi: 10.1016/s0076-6879(78)52009-0. [DOI] [PubMed] [Google Scholar]
  52. Tomasz M., Lipman R., Chowdary D., Pawlak J., Verdine G. L., Nakanishi K. Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. Science. 1987 Mar 6;235(4793):1204–1208. doi: 10.1126/science.3103215. [DOI] [PubMed] [Google Scholar]
  53. Wang W., Higuchi C. M. Induction of NAD(P)H:quinone reductase by vitamins A, E and C in Colo205 colon cancer cells. Cancer Lett. 1995 Nov 27;98(1):63–69. [PubMed] [Google Scholar]
  54. Workman P., Stratford I. J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev. 1993 Jun;12(2):73–82. doi: 10.1007/BF00689802. [DOI] [PubMed] [Google Scholar]
  55. Xu B. H., Gupta V., Singh S. V. Characterization of a human bladder cancer cell line selected for resistance to mitomycin C. Int J Cancer. 1994 Sep 1;58(5):686–692. doi: 10.1002/ijc.2910580512. [DOI] [PubMed] [Google Scholar]
  56. Zhang Y., Kensler T. W., Cho C. G., Posner G. H., Talalay P. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3147–3150. doi: 10.1073/pnas.91.8.3147. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES